C

Corbus Pharmaceuticals Holdings

D
CRBP
USD
-0.36
(-1.8799%)
Market Open
36,659.00
Volume
-3.77
EPS
-
Div Yield
-3.238342
P/E
225,462,556.80
Market Cap
Today
-0.8985%
1 Week
13.430%
1 Month
-2.344%
6 Months
-51.837%
12 Months
272.024%
Year To Date
193.427%
All Time
-90.809%

Title:
Corbus Pharmaceuticals Holdings

Sector:
Healthcare
Industry:
Biotechnology
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Do you need help or have a question?